2-(2-(4,5-Dihydro-1H-imidazol-2-yl)-1-pyridine-2-ylethyl)quinoline | 425393-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(2-(4,5-Dihydro-1H-imidazol-2-yl)-1-pyridine-2-ylethyl)quinoline
• 英文别名: 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-pyridin-2-ylethyl]quinoline
• CAS: 425393-88-0
• 化学式: C₁₉H₁₈N₄
• 分子量: 302.379
• InChiKey: ASHBSAHXRJVGSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Oral hypoglycaemic agents
  申请人：——

  公开号：US20020132812A1

  公开（公告）日：2002-09-19

  Compounds of formula (I) which are optionally substituted 2-(&ohgr;,&ohgr;-diarylalkyl)-4,5-dihydro-1H-imidazoles and 2-(&ohgr;,&ohgr;-diarylalkyl)-1,4,5,6-tetrahydropyrimidines and salts thereof with inorganic and organic acids have interesting pharmacological properties. Thus, the compounds are useful in the treatment of type 2 diabetes.

  式(I)的化合物，它们是可选择取代的2-(&ohgr;，&ohgr;-二芳基烷基)-4,5-二氢-1H-咪唑和2-(&ohgr;，&ohgr;-二芳基烷基)-1,4,5,6-四氢嘧啶及其与无机和有机酸的盐具有有趣的药理特性。因此，这些化合物在治疗2型糖尿病方面是有用的。
• [EN] 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS<br/>[FR] COMPOSES 1,3 DIAZHETEROCYCLIQUES ET UTILISATION DE CES DERNIERS COMME AGENTS HYPOGLYCEMIANTS
  申请人：NOVO NORDISK AS

  公开号：WO2002038559A1

  公开（公告）日：2002-05-16

  A compound of formula (I) wherein Y is selected from the ring systems (a), (b); R?1 and R2¿ are independently phenyl, naphthyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, quinolyl, 3-4-dihydroquinolyl, 5,6,7,8-tetrahydroquinolyl, isoquinolyl, 3,4-dihydroisoquinolyl, 5,6,7,8-tetrahydroisoquinolyl, indolyl, benzo[b]thienyl, benzimidazozyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyridyl or benzthiazolyl each of which is optionally substituted. R?3 and R5¿ are independently hydrogen, C¿1-6? alkyl or halogen or when taken together R?3 and R5¿ form an additional bond between the carbon atoms which they are attached; R¿4? is hydrogen, C1-6alkyl, arylC1-6alkyl, C1-6-C(O)- or arylC1-6alkyl-C(O)-, X is -CR?18R19¿- wherein R?18 and R19¿ are independently hydrogen or C¿1-6?alkyl; n is 0, 1 or 2. Thus, the compounds are useful in the treatment of type 2 diabetes.